Bluebee

White paper: Bluebee Data security and compliance

Bluebee offers a global bio-informatics platform to process, analyze, share and store genomics data. With a private cloud service, Bluebee supports users in clinical diagnostics, therapeutics and research with advanced analytics for genomic data driven medicine. Designed for cross-functional teams of clinicians and life science researchers the Bluebee platform effectively centralizes and manages genomics data processes and storage. Bluebee’s multi-layered …

5 minutes with Dr Subhadra Dravida, Founder and CEO of Transcell

Transcell Biologics is an innovative biotech company focuses in anti-cancer treatment, neurological ailments and autoimmune disorder. The innovative, stem cell based biotech company is based in Hyderabad, India. Ahead of this year’s BioPharma India 2016, we had the pleasure of grabbing a few minutes with its founder and CEO, Dr Subhadra Dravida.   What sparked the establishment of Transcell? We hope to translate stem cell …

The art of repositioning drugs: An interview with NovaLead Pharma’s Supreet Deshpande

Inventing a new drug requires huge financial commitment and it’s a lengthy process until it reaches patients in need. However, discovering a new application of an already clinically-approved drug saves you both time and allows you to fully utilise the power of your existing arsenal. Since the original drug application has a known function and toxicity, drug repurposing saves time and …

Increase in Continuous Processing and Single-Use in Future Biomanufacture Forecast in New Review

A review by Institute for Separation and Process Technology has predicted an increase in the use of single use technologies and continuous processing within the manufacture of biologics in the future. Researchers Jochen Strube, Reinhard Ditz and Petra Gronemeyer, predict that demands for high quality biologics will continue to increase in the coming decades. Decreasing production and imminent patent expirations of ‘blockbuster’ drugs coupled with a …

Download: Exploring the global Pharma M&A market

Andrew Badrot, Founder of CMS Pharma kindly shared his thoughts on the Pharma M&A market, the challenges being faced and what companies can do to overcome the hurdles. Download a copy here The Pharma Mergers and Acquisitions market has recently seen a lot of traffic, with deals between GlaxoSmithKline and Novartis, whilst Pfizer has made overtures to AstraZeneca. With activity …

Pharma M&A Forecast Sunny

Sunny with little chance of rain: Pharma M&A forecast

Pharma M&A activity is hot out the blocks for the first quarter, with activity in the Pharma, Medical & Biotech sector totaling $63.4 billion, higher than its 2013 counterpart at $14.2 billion.   On 9th April Mergermarket released its Global Q1 2014  Pharma, Medical & Biotech M&A Trend Report,  identifying large scale growth in the pharmaceutical sector, compared to last year. …

GPCB issues closure notice to Zydus Cadila research unit

Gujarat Pollution Control Board (GPCB) has issues a closure notice to Zydus Cadila’s research unit in Ahmedabad for allegedly polluting ground water. They received a complaint from people that their unit at Moraiya area has been discharging polluted effluents to ground water. Upon receiving the complaints, GPCB officials inspected the area and found the irregularities, violating provisions of the Prevention …

Teva’s New CEO Moves Quickly on Dealmaking

Recently, pharmaceutical company Teva has been facing numerous challenges. These include expiring patents for their top drugs, strong labour opposition to plans for restructuring, conflict between the Board of Directors and Management which resulted in the CEO’s departure, and shareholder unrest. Eyal Desheh, the CFO, has said that they have to make smart deals and partnerships like how Teva has …